Abstract:Background: The disease activity evaluation of Takayasu arteritis (TA) is a critical issue for disease monitoring and treatment. But the previous markers such as Kerr score or ITAS 2010 are not convenient enough. Objectives: We aim to explore novel biomarkers to assess TA disease activity. Methods: This cross-sectional study was based on the East China TA (ECTA) cohort. Demographic characteristics, clinical features, laboratory and imaging results were collected. Complements and their combination with other biomarkers in identifying active disease (Kerr >= 2) group were analyzed. Internal and external validation were employed to confirm the accuracy and stability of the results. Results: 519 patients were enrolled, among which 406 cases (72.2%) were identified as active disease. Higher ESR, CRP, platelet, globulin, IgG, IL-6, complement 3 (C3), complement 4 (C4) and median haemolytic complement (CH50) levels were observed in the active disease group. Logistic regression analysis demonstrated that C3 levels [odds ratio [OR] (95%CI): 10.710(1.825 – 62.835), P = 0.009] and CRP [OR (95%CI): 1.041(1.009 – 1.073), P = 0.011] were independently associated with active disease. The cut-off of C3 to identify active TA was 1.085 g/L, with 69.9% sensitivity, 66.7% specificity. Combining the CRP (cut-off, 10.65g/L; sensitivity, 50.7%; specificity, 82.4%) and C3, the sensitivity and specificity to identify the active disease were 85.1% and 55.0% (parallel test), and 35.4% and 94.1% (serial test), respectively. C3 could significantly improve the diagnostic ability of CRP [net reclassification index: OR (95%CI): 1.728 (1.556–1.990), P = 0.000; integrated discrimination index: OR (95%CI): 0.328 (0.224–0.431), P = 0.000]. The accuracy of the 10-fold cross validation of combining CRP with C3 was over 75%, and the accuracy of the external validation with 53 TA cases was 72.73%. Conclusion: C3 could reflect the disease activity of TA, and combining CRP with C3 could significantly improve the disease activity evaluation in TA. References: [1]Ma J, Luo X, Wu Q, Chen Z, Kou L, Wang H. Circulation levels of acute phase proteins in patients with Takayasu arteritis. J Vasc Surg. 2010;51(3):700-6. Acknowledgments: This work was supported by the National Natural Science Foundation of China [NSFC 81771730 and 81601398]. Disclosure of Interests: : None declared

Elevated Plateletcrit Levels Could Predict 6-Month Treatment Response in Takayasu Arteritis

The Role of Plateletcrit in Takayasu Arteritis: A Potential Biomarker for Disease Activity and 6‐month Treatment Response

Analysis of Predictive Factors for Treatment Resistance and Disease Relapse in Takayasu's Arteritis

MMP-9 and IL-6 Are Potential Biomarkers for Disease Activity in Takayasu's Arteritis

Decreased Absolute Number of Circulating Regulatory T Cells in Patients With Takayasu’s Arteritis

Study on clinical characteristics and therapeutic outcomes of 173 patients with Takayasu arteritis

YKL-40 As a New Biomarker of Disease Activity in Takayasu Arteritis.

Retrospective Study of 67Patients with Takayasu Arteritis

Evaluation of Takayasu Arteritis Activity by Delayed Contrast-Enhanced Magnetic Resonance Imaging

ELEVATED COMPLEMENT 3 INDICATES DISEASE ACTIVITY IN TAKAYASU ARTERITIS

Treatment of Takayasu Arteritis with the IL-6R Antibody Tocilizumab Vs. Cyclophosphamide.

Analysis of clinical features between active and inactive patients of Takayasu's arteritis with pulmonary arteries involvement

Single-Cell RNA Sequencing Revealed CD14+ Monocytes Increased in Patients With Takayasu’s Arteritis Requiring Surgical Management

Potential Role of Macrophage Phenotypes and CCL2 in the Pathogenesis of Takayasu Arteritis.

Value of Whole-Body Contrast-Enhanced Magnetic Resonance Angiography with Vessel Wall Imaging in Quantitative Assessment of Disease Activity and Follow-Up Examination in Takayasu’s Arteritis

Novel Biomarkers for the Precisive Diagnosis and Activity Classification of Takayasu Arteritis

The Critical Role of IL-6 in the Pathogenesis of Takayasu Arteritis.

Exploration of Molecular Signatures Associated with Different Clinical Features of Takayasu Arteritis Based on a Prospective Cohort Study.

Enhanced Liver Fibrosis Score as a Biomarker for Vascular Damage Assessment in Patients with Takayasu Arteritis—A Pilot Study

Evaluation of clinical measurements and development of new diagnostic criteria for Takayasu arteritis in a Chinese population.

18 F-FDG-PET/CT: an accurate method to assess the activity of Takayasu’s arteritis